JCC: 溃疡性结肠炎患者第6周的戈利木单抗低谷水平与不良预后相关

2019-11-08 不详 MedSci原创

戈利木单抗在治疗溃疡性结肠炎[UC]患者疗效已得到公认。然而,血清戈利木单抗谷水平[TL]与疾病活动性的客观标志物(如内窥镜和组织学活动评分以及生物标志物浓度)之间的关系仍然鲜为人知。本项研究旨在探究诱导期[第6周]结束时血清戈利木单抗TL与临床,内镜,组织学和生物标志物参数的关系。

背景和目标
戈利木单抗在治疗溃疡性结肠炎[UC]患者疗效已得到公认。然而,血清戈利木单抗谷水平[TL]与疾病活动性的客观标志物(如内窥镜和组织学活动评分以及生物标志物浓度)之间的关系仍然鲜为人知。本项研究旨在探究诱导期[第6周]结束时血清戈利木单抗TL与临床,内镜,组织学和生物标志物参数的关系。

方法
这是一项前瞻性干预性研究。所有患者均为未接受生物治疗的中度至重度活动的UC患者接受戈利木单抗治疗。在基线[诱导的第0周]和第6周测量血清戈利木单抗TL和粪便钙卫蛋白水平。

结果
共有34位患者完成了诱导期[第6周],并纳入了该分析。总体而言,在有早期反应或缓解的患者中,分别有47.1%和14.7%的患者实现了临床缓解和缓解,血清戈利木单抗TL明显升高[3.7μg/mL VS 1.3μg/mL,p=0.0013;3.1μg/mL VS 1.7μg/mL,p=0.0164]。此外,达到组织学缓解的患者戈利木单抗TL明显更高[ 4.2μg/mL VS 1.7μg/mL,p=0.0049]。第6周戈利木单抗 TL与Mayo总评分呈负相关[r=-0.546; p=0.0008],Mayo内镜评分[r=-0.381; p=0.0262],Geboes组织学活动评分[r=-0.464; p=0.0057],粪便钙卫蛋白水平[r=-0.497; p=0.0044]。

结论
在活动性UC患者中,较高的早期戈利木单抗血清浓度与更好的临川反应相关,并且在第6周的血清浓度可以很好的进行预测。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695123, encodeId=c4f41695123fb, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Thu Oct 01 20:58:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336395, encodeId=a5c8133639504, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Sun Nov 10 14:58:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497472, encodeId=fa31149e472d9, content=<a href='/topic/show?id=4f465380215' target=_blank style='color:#2F92EE;'>#戈利木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53802, encryptionId=4f465380215, topicName=戈利木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49569326738, createdName=FukaiBao, createdTime=Sun Nov 10 14:58:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2020-10-01 nymo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695123, encodeId=c4f41695123fb, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Thu Oct 01 20:58:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336395, encodeId=a5c8133639504, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Sun Nov 10 14:58:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497472, encodeId=fa31149e472d9, content=<a href='/topic/show?id=4f465380215' target=_blank style='color:#2F92EE;'>#戈利木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53802, encryptionId=4f465380215, topicName=戈利木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49569326738, createdName=FukaiBao, createdTime=Sun Nov 10 14:58:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695123, encodeId=c4f41695123fb, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Thu Oct 01 20:58:00 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336395, encodeId=a5c8133639504, content=<a href='/topic/show?id=071820530c5' target=_blank style='color:#2F92EE;'>#不良预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20530, encryptionId=071820530c5, topicName=不良预后)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c97a2500111, createdName=thinkibmz_44722594, createdTime=Sun Nov 10 14:58:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497472, encodeId=fa31149e472d9, content=<a href='/topic/show?id=4f465380215' target=_blank style='color:#2F92EE;'>#戈利木单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53802, encryptionId=4f465380215, topicName=戈利木单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49569326738, createdName=FukaiBao, createdTime=Sun Nov 10 14:58:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]

相关资讯

Golimumab治疗外周型SpA的疗效评估

根据美国风湿病学会年会上提出的研究结果,单克隆抗体戈利木单抗(golimumab)治疗外周型脊柱关节炎后,75%的患者经历临床缓解。 来自比利时根特大学教学医院的Philippe Carron博士和同事们对60例活跃的外周型脊柱关节炎(SpA)患者进行了研究,使用golimumab (Simponi, Janssen)或安慰剂治疗,评估诱导治疗后的吴无药物持续临床缓解和复发风险。 40

Inflam Bowel Dis: Golimumab的连续临床反应与重度溃疡性结肠炎患者病程变化相关

在溃疡性结肠炎(UC)患者中使用golimumab维持治疗时,有约50%的患者接受诱导治疗的持续临床反应(CCR)会持续1年。本项研究旨在探究连续临床反应与golimumab治疗效果的关系。

GUT : 戈利木单抗治疗IBD的效果分析

现在越来越多的生物制剂可以用于治疗炎症性肠病(IBD),本项研究旨在了解戈利木单抗在“真实世界”环境中的有效性。